In a report released today, Yaron Werber from TD Cowen maintained a Buy rating on Roivant Sciences (ROIV – Research Report). The company’s ...

Immunovant and Roivant Sciences said Wednesday their rare disease drug succeeded in a final-phase study, but the duo won't seek approval.

Immunovant (Nasdaq: IMVT), a Roivant Sciences company, today reported top-line results from its Phase III study of batoclimab ...

Cargo was founded by two highly acclaimed cell-therapy researchers. The company raised over $500 million to develop ...

Pivotal study in MG met primary endpoint of change from baseline in MG-ADL in AChR+ population at 12 weeks, with a 5.6 point improvement in the ...

Immunovant (NASDAQ:IMVT) traded lower in the premarket on Wednesday after the company announced clinical trial data related ...

The companies reported Wednesday that batoclimab showed improvements in myasthenia gravis patients in a Phase 3 trial.

Roivant Sciences Ltd. CEO Matt Cline said the firm’s unit Immunovant Inc. with FcRn blocker batoclimab has established “frankly a new bar” in myasthenia gravis (MG) as the New York-based firm reported ...

Leading the way with our groundbreaking research and innovative teaching spanning chemistry, physics and astronomy, and mathematics and statistics. Our students go on to make an impact across a huge ...

State of Michigan Retirement System lessened its holdings in Roivant Sciences Ltd. (NASDAQ:ROIV – Free Report) by 1.8% during the fourth quarter, Holdings Channel.com reports. The institutional ...

WORKFORCE CUTS. I KNOW, I KNOW, RESEARCHERS, SCIENTISTS, STUDENTS AND RAGING GRANNIES STANDING UP FOR SCIENCE AT THE CALIFORNIA STATE CAPITOL. I WAS A TEACHER, AND THIS IS A LOT ABOUT EDUCATION.